EP4469045A4 - Utilisation d'ergothionéine pour prolonger la durée de vie ou améliorer la santé - Google Patents

Utilisation d'ergothionéine pour prolonger la durée de vie ou améliorer la santé

Info

Publication number
EP4469045A4
EP4469045A4 EP23746065.4A EP23746065A EP4469045A4 EP 4469045 A4 EP4469045 A4 EP 4469045A4 EP 23746065 A EP23746065 A EP 23746065A EP 4469045 A4 EP4469045 A4 EP 4469045A4
Authority
EP
European Patent Office
Prior art keywords
ergothioneine
improve health
extend lifespan
lifespan
extend
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23746065.4A
Other languages
German (de)
English (en)
Other versions
EP4469045A1 (fr
Inventor
Kylin Liao
Joseph L Evans
Qiru Fan
Shawn Wells
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Nutrabuilding Bio Tech Co Ltd
Original Assignee
Nanjing Nutrabuilding Bio Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Nutrabuilding Bio Tech Co Ltd filed Critical Nanjing Nutrabuilding Bio Tech Co Ltd
Publication of EP4469045A1 publication Critical patent/EP4469045A1/fr
Publication of EP4469045A4 publication Critical patent/EP4469045A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP23746065.4A 2022-01-27 2023-01-16 Utilisation d'ergothionéine pour prolonger la durée de vie ou améliorer la santé Pending EP4469045A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022074358 2022-01-27
PCT/CN2023/072351 WO2023143183A1 (fr) 2022-01-27 2023-01-16 Utilisation d'ergothionéine pour prolonger la durée de vie ou améliorer la santé

Publications (2)

Publication Number Publication Date
EP4469045A1 EP4469045A1 (fr) 2024-12-04
EP4469045A4 true EP4469045A4 (fr) 2025-11-26

Family

ID=87470544

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23746065.4A Pending EP4469045A4 (fr) 2022-01-27 2023-01-16 Utilisation d'ergothionéine pour prolonger la durée de vie ou améliorer la santé

Country Status (5)

Country Link
EP (1) EP4469045A4 (fr)
CN (1) CN118524837A (fr)
AU (1) AU2023210881A1 (fr)
CA (1) CA3249801A1 (fr)
WO (1) WO2023143183A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025051119A1 (fr) * 2023-09-06 2025-03-13 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Approche visant à réduire ou inhiber les produits de glycation avancée

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160067221A1 (en) * 2014-09-05 2016-03-10 China Medical University Use of ergothioneine for inducing activity of nrf2 in cell
WO2021158601A1 (fr) * 2020-02-03 2021-08-12 Blue California Méthodes et compositions associées à l'utilisation d'ergothionéine
WO2022242711A1 (fr) * 2021-05-20 2022-11-24 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Méthodes d'amélioration et de prévention de la dégénérescence musculaire liée à l'âge
US11534426B1 (en) * 2022-01-26 2022-12-27 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Use of ergothioneine for extending lifespan or improving healthspan

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103181933B (zh) * 2011-12-31 2014-08-20 中国科学院天津工业生物技术研究所 富含麦角硫因的功能性口服制剂的制备方法
MX2022001087A (es) * 2019-07-26 2022-04-07 Fundacio Inst Dinvestigacio Biomedica De Bellvitge Idibell Ergotioneina, s-metil-ergotioneina, y usos de las mismas.
CN112641777B (zh) * 2021-01-07 2023-02-03 山东华熙海御生物医药有限公司 麦角硫因类物质在制备防治缺血性脑卒中药物中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160067221A1 (en) * 2014-09-05 2016-03-10 China Medical University Use of ergothioneine for inducing activity of nrf2 in cell
WO2021158601A1 (fr) * 2020-02-03 2021-08-12 Blue California Méthodes et compositions associées à l'utilisation d'ergothionéine
WO2022242711A1 (fr) * 2021-05-20 2022-11-24 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Méthodes d'amélioration et de prévention de la dégénérescence musculaire liée à l'âge
US11534426B1 (en) * 2022-01-26 2022-12-27 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Use of ergothioneine for extending lifespan or improving healthspan

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEELMAN ROBERT B. ET AL: "Is ergothioneine a 'longevity vitamin' limited in the American diet?", JOURNAL OF NUTRITIONAL SCIENCE, vol. 9, no. e52, 11 November 2020 (2020-11-11), GB, pages 1 - 5, XP093324146, ISSN: 2048-6790, DOI: 10.1017/jns.2020.44 *
See also references of WO2023143183A1 *

Also Published As

Publication number Publication date
EP4469045A1 (fr) 2024-12-04
WO2023143183A1 (fr) 2023-08-03
CN118524837A (zh) 2024-08-20
CA3249801A1 (fr) 2023-08-03
AU2023210881A1 (en) 2024-08-22

Similar Documents

Publication Publication Date Title
EP4093513A4 (fr) Utilisations de biomarqueurs pour améliorer une immunothérapie
EP4308128A4 (fr) Méthodes améliorées pour l'utilisation de psychédéliques
EP4125837A4 (fr) Utilisation de combinaisons de bupropion et de dextrométhorphane pour le traitement de troubles neurologiques
EP4312802A4 (fr) Utilisation de paraxanthine pour réduire la fatigue mentale induite par l'exercice
EP4107943A4 (fr) Codage de sous-images voisines
EP3969113C0 (fr) Utilisation d'un sucre ou d'un alcool de sucre
EP4469045A4 (fr) Utilisation d'ergothionéine pour prolonger la durée de vie ou améliorer la santé
EP4226924A4 (fr) Utilisation de pénéhyclidine dans le traitement ou la prévention de maladies oculaires nuisant à la vision
EP4360641A4 (fr) Utilisation de mazdutide
EP4135683C0 (fr) Utilisation de pleuromutilines comme antivirals
EP4051277A4 (fr) Méthodes de traitement de la leucémie et utilisation d'une signature de cellules souches leucémiques pour prédire la sensibilité clinique à des thérapies
EP4268522A4 (fr) Ul-tdoa et dl-tdoa pour une amélioration de la précision
EP4356142A4 (fr) Biomarqueurs et combinaisons de médicaments pour la prédiction de l'insuffisance cardiaque
EP3941451A4 (fr) Compositions comprenant des lipides polaires pour maintenir ou augmenter la mobilité et la vitalité
EP4397315A4 (fr) Composition pour améliorer l'immunogénicité
EP4153168A4 (fr) Utilisation de terpénoïdes dans le traitement ou la prévention de maladies fibrotiques
IL291424A (en) Use of dkk-1 inhibitors for treating cancer
EP4209579A4 (fr) Bifidobactérie inhibant l'expression d'un gène de l'atrophie musculaire
EP4426297A4 (fr) Utilisations de pan-inhibiteurs de bet
EP4349335A4 (fr) Utilisation de la 5-nitro-8-hydroxyquinoléine
EP4262870A4 (fr) Utilisation d'une immunothérapie ciblant la fibrine pour réduire la pathogenèse du coronavirus
EP4181960A4 (fr) Stimulation sonogénétique de cellules exprimant trpa1
EP4363056A4 (fr) Utilisation de terpénoïdes dans le traitement ou la prévention de maladies fibrotiques
EP4460300A4 (fr) Utilisation d'ergothionéine pour améliorer le taux de glutathion
EP3756689A4 (fr) Inhibiteur de l'activité de l'il-17a et son utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240827

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20251028

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4172 20060101AFI20251022BHEP

Ipc: A61P 39/06 20060101ALI20251022BHEP